Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: A 20-year cohort study of 3.8 million vaccinees

Abstract

Hepatitis B immunization has been documented to prevent fulminant hepatic failure (FHF) and hepatocellular carcinoma (HCC) by historical comparison studies in Taiwan. This study aimed to assess long-term risks and predictors of various liver diseases associated with incomplete immunization in 3.8 million vaccinees. Profiles of the National Hepatitis B Immunization Registry, National Cancer Registry, and National Death Certification Registry were linked to ascertain newly diagnosed cases of HCC and deaths from FHF and chronic liver diseases (CLDs) from infancy to early adulthood of 3,836,988 newborn vaccinees. Cox's proportional hazards models were used to estimate hazard ratios (HRs) for various risk predictors. There were 49 newly developed cases of HCC, 73 deaths from FHF, and 74 deaths from CLDs during the follow-up of 41,854,715 person-years. There were striking differences between unvaccinated and vaccinated newborns after the launch of a national immunization program for HCC incidence (0.293 vs. 0.117 per 100,000 person-years), FHF mortality (0.733 vs. 0.174 per 100,000 person-years), and CLD mortality (2.206 vs. 0.177 per 100,000 person-years). Among vaccinees, incomplete immunization was the most important risk predictor of HCC, FHF, and CLDs, showing an HR (95% confidence interval, P value) of 2.52 (1.25-5.05; P 5 0.0094), 4.97 (3.05-8.11; P < 0.0001), and 6.27 (3.62-10.84; P < 0.0001), respectively, after adjustment for maternal hepatitis B serostatus. Conclusion: Hepatitis B immunization can significantly prevent the long-term risk of HCC, FHF, and CLDs from infancy to early adulthood. Incomplete immunization with hepatitis B immunoglobulin or vaccines was the most important risk predictor of the liver disease among vaccinees. (HEPATOLOGY 2014;60:125-132)

Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets

“…The risk of chronic HBV infection, despite HBV birth-dose vaccination, is 3•74 times higher if the interval between the first and second vaccine doses is more than 10 weeks, making adherence to appropriate vaccine schedules essential. 48 A Taiwanese study 49 ; HRs calculated after adjustment for maternal HBsAg status) in those who become infected with HBV. Unfortunately, full vaccine coverage with three HBV vaccine doses is poor: WHO-UNICEF estimated that in 2015, only 77% of infants in Africa received full vaccine coverage.…”

Higher disappearance rate of anti‐HBs in Taiwanese freshers neonatally vaccinated with recombinant yeast hepatitis B vaccine

“…13,14 Chien et al found that incomplete neonatal immunization would cause higher incidence for hepatocellular carcinoma, mortality of fulminant hepatic failure and chronic liver diseases as compared with completely vaccinated newborns. 15 Moreover, application of different types or doses of vaccines may also influence primary antibody responses, development of immune memory and mean anti-HBs levels. [16][17][18] Some studies mentioned about the efficacy of different types of vaccines.…”

Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994

“…In conclusion, the present study showed a high incidence of HBV infection and a dramatically low level of protection against hepatitis B among young French adults at risk of sexually transmitted diseases. Studies evaluating the impact of mass vaccination campaigns against HBV, in particular from the Taiwanese experience, have shown that such campaigns dramatically reduced HBsAg prevalence and the incidence of feared complications of HBV infection, in particular fulminant hepatitis and hepatocellular carcinoma [26,27]. In Europe, the best vaccination policy is still under debate; the majority of European countries have universal HBV vaccination programmes, whereas six countries prefer targeting high-risk groups [28,29].…”